Sisunatovir - ReViral
Alternative Names: PF-07923568; RV-521; RV521.HCl; Sisunatovir hydrochloride - ReViralLatest Information Update: 18 Oct 2024
Price :
$50 *
At a glance
- Originator ReViral
- Developer Pfizer; ReViral
- Class Antivirals; Benzimidazoles; Cyclopropanes; Fluorinated hydrocarbons; Indoles; Small molecules
- Mechanism of Action Viral fusion protein inhibitors; Virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Respiratory syncytial virus infections
- Phase I Renal failure
Most Recent Events
- 08 Oct 2024 Pfizer terminates phase II/III trial in Respiratory syncytial virus infections (In adults, In the elderly) in USA (PO, Tablet), due to business reasons (NCT06079320)
- 08 Sep 2024 Pharmacokinetics data from the phase I trial in Respiratory Syncytial virus infections presented at the 2024 American College of Clinical Pharmacology Annual Meeting (ACCP-2024)
- 08 Sep 2024 Pharmacokinetics data from the preclinical studies in Respiratory Syncytial virus infection presented at the 2024 American College of Clinical Pharmacology Annual Meeting (ACCP-2024)